Can drug monitoring make a common lung cancer treatment safer and more effective?

NCT ID NCT06195527

Recruiting now Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is looking at whether regularly checking the amount of pembrolizumab in the blood of people with non-small cell lung cancer can help doctors tailor treatment. The goal is to see if this monitoring can improve how well the drug works and reduce side effects. The trial will enroll 75 adults already receiving pembrolizumab as part of their standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab
What this could lead to: If successful, this could help doctors personalize pembrolizumab dosing for lung cancer patients, potentially improving outcomes and reducing side effects.
What could go wrong: This is a small, early-phase observational study (75 participants) that does not test a new treatment. It may not find a clear link between drug levels and response, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Angers University Hospital
RECRUITING

Angers, 49000, France
CH Le Mans
NOT_YET_RECRUITING

Le Mans, 53000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.